The product will be developed at the group's Baddi facility in Himachal Pradesh.
BFI-751 is being developed as a biosimilar to Stelara (Ustekinumab).
There were no reported adverse events for Albuterol Sulphate Inhalation Aerosol.
It will closely work with existing and new business partners to expand its footprint.
It is scheduled to open in 2023 and will include a cutting-edge healthcare facility with a total of 126 beds.
The phase 3 trial is a multi-center, randomized, double-blind study of females with metastatic HER2-positive breast cancer.
This nasal spray is a generic version of Par Pharmaceutical, Inc.'s Nascobal Nasal Spray.
Palbociclib is used to treat a specific type of breast cancer.
The report added that the auditors also noticed raw materials being kept in extremely hot and humid circumstances.
The divestment agreement is expected to be completed by the end of July 2023.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
